Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2, 2019. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
| Metric | Value |
|---|---|
| Issued Share Capital (as of Dec 31, 2018) | 5,379,067,624 Ordinary Shares (25 pence each) |
| Treasury Shares | 414,605,950 |
| Total Voting Rights | 4,964,461,674 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period regarding financial performance or operational metrics. The document only states the static capital position as of December 31, 2018.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The primary purpose of this filing is to establish the denominator for shareholder notification calculations under FCA rules.
Important Facts for Investors
- Voting Rights Denominator: Shareholders must use 4,964,461,674 as the total number of voting rights to determine if they are required to notify the Company of their interest or changes thereto.
- Treasury Holdings: Approximately 414.6 million shares are held in Treasury and do not carry voting rights.
- Reporting Date: The capital figures reflect the status as of December 31, 2018, notified on January 2, 2019.